-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $127

Benzinga·12/09/2025 17:19:31
Listen to the news
Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $73 to $127.